Vaxcyte, Inc.

NASDAQ:PCVX

73.02 (USD) • At close March 13, 2025
Bedrijfsnaam Vaxcyte, Inc.
Symbool PCVX
Munteenheid USD
Prijs 73.02
Beurswaarde 9,402,201,240
Dividendpercentage 0%
52-weken bereik 58.1 - 121.055
Industrie Biotechnology
Sector Healthcare
CEO Mr. Grant E. Pickering M.B.A.
Website https://vaxcyte.com

An error occurred while fetching data.

Over Vaxcyte, Inc.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to

Vergelijkbare Aandelen

Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.

SUPN

31.17 USD

Dynavax Technologies Corporation logo

Dynavax Technologies Corporation

DVAX

13.69 USD

Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc.

XENE

35.18 USD

Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc.

TVTX

19.13 USD

Krystal Biotech, Inc. logo

Krystal Biotech, Inc.

KRYS

177.37 USD

ImmunityBio, Inc. logo

ImmunityBio, Inc.

IBRX

2.9 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)